Shots: The first patient has been dosed in the P-IIII inMIND study assessing the efficacy and safety of tafasitamab vs PBO in combination with lenalidomide and rituximab in patients with […]readmore
Tags : Marginal Zone Lymphoma
Shots: The approvals is based on P-II UNITY-NHL trial involves assessing Ukoniq (800 mg, qd) in 69 patients with MZL who has received at least 1 prior anti-CD20 based regimen […]readmore
Shots: The data includes P-l/lla study involves assessing BI-1206 + rituximab in patients with FL, MZL and MCL who have r/r to rituximab. The study demonstrated at BI-1206 is generating […]readmore
Pharma
Regulatory
Bayer’s Aliqopa (copanlisib) Receives the US FDA’s Breakthrough Therapy Designation
Shots: The BT Designation is based on the P-II CHRONOS-1 study which involves assessing of 25 patients with relapsed or refractory MZL who have received at least two prior therapies […]readmore
Shots: The approval is based on P-III AUGMENT study results assessing Revlimid + Rituximab (R2) vs rituximab + PBO in patients with previously treated FL & MZL, following its PR […]readmore